### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ \ Origin: Appendix 5 \ \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 1/03/13$ 

Name of entity

Boss Resources Limited	
ABN	
38 116 834 336	

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

\*Class of \*securities issued or to be **Ordinary Fully Paid Shares** Number of \*securities issued or to 2 104,615,385 be issued (if known) or maximum number which may be issued Principal terms of the \*securities **Ordinary Fully Paid Shares** 3 (e.g. if options, exercise price and partly expiry date; if paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) Do the \*securities rank equally in 4 all respects from the +issue date with an existing +class of quoted +securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they

+ See chapter 19 for defined terms.

participate

distribution)

payment

for

dividend, (in the case of a trust,

the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

or

the

interest

5	Issue price or consideration	\$0.065 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Working capital raising placement to sophisticated and institutional investors as per announcement dated 20 January 2017
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2016
6c	Number of *securities issued without security holder approval under rule 7.1	104,615,385
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	Nil
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

30 January 2017	

8 Number and \*class of all \*securities quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class		
1,007,291,021	Fully	Paid	Ordinary
	Shares		

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
10,000,000	Unlisted options with an exercise price of \$0.02 expiring 31 August 2018
10,000,000	Performance rights vesting on trading price of \$0.075 for 20 consecutive days
3,333,333	Performance rights vesting on trading price of \$0.085 for 20 consecutive ASX trading days
13,333,333	Performance rights vesting on discovery of 75,000t of contained Ni at 2% (or equivalent) or equivalent Cu or PGE mineralisation which the Company decides to mine in Europe
13,333,333	Performance rights vesting on discovery of 125,000t of contained Ni at 2% (or equivalent) or equivalent Cu or PGE

<sup>+</sup> See chapter 19 for defined terms.

	mineralisation which the Company decides to mine in Europe
2,000,000	Performance rights vesting on 12 months service.
2,000,000	Performance rights vesting on 24 months service.
3,000,000	Performance rights vesting on facilitation and completion of a capital raising for an amount not less than \$5,000,000.
3,000,000	Performance rights vesting when the closing price of BOE shares is at or above \$0.085 for 20 consecutive ASX trading days.
8,000,000	Performance rights vesting on ASX announcement confirming the successful raise of the capital expenditure required for the extended plant construction as contemplated by a Board approved definitive feasibility study.
1,250,000	Performance rights vesting when the closing price of BOE shares is at or above \$0.085 for 20 consecutive ASX trading days.
1,000,000	Performance rights vesting upon estimation of a 30mlb JORC Resource of U <sub>3</sub> O <sub>8</sub> in the Measured and Indicated categories from the

		250,000	Eastern Tenements of the Company's Honeymoon Uranium Project.  Performance rights vesting upon estimation of a 33mlb JORC Resource of U <sub>3</sub> O <sub>8</sub> in the Measured and Indicated categories from the Eastern Tenements of the Company's Honeymoon Uranium Project.
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Unchanged	
Part	2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A	
15	<sup>+</sup> Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A	

<sup>+</sup> See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Issue date	N/A

#### Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of \*securities 34 (tick one) (a) +Securities described in 2(a) in Part 1 (b) All other \*securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional +securities, and the number and percentage of additional +securities held by those holders 36 If the \*securities are \*equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional +securities 37 Entities that have ticked box 34(b)

Number of \*securities for which

\*Class of \*securities for which

<sup>+</sup>quotation is sought

quotation is sought

38

39

04/03/2013 Appendix 3B Page 7

N/A

N/A

<sup>+</sup> See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 30 January 2017

(Director/Company secretary)

Print name: Oonagh Malone

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	854,758,969	
<ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	31,250,000 (7 June 2016 – approved 16 August 2016)  16,666,667 (24 August 2016 – approved 16 August 2016)  Nil	
"A"	902,675,636	

Step 2: Calculate 15% of "A"			
"B"	0.15		
	[Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	135,401,345		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule		
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	104,615,385		
Under an exception in rule 7.2			
Under rule 7.1A			
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>			
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"C"	104,615,385		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	135,401,345		
Note: number must be same as shown in Step 2			
Subtract "C"	104,615,385		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.15] – "C"	30,785,960		
	[Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

Rule 7.1A – Additional placement capacity for eligible entities  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<b>Multiply</b> "A" by 0.10	90,267,564
7.1A that has already been used  Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"E"	Nil

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	90,267,564
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	90,267,564
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.